Immunosuppressive therapy is a major mode of preventing rejection of kidney transplant(KT)recipients.To standardize the application of immunosuppressants for KT recipients,the Organ Transplantation Branch of Chinese Medical Association initiated the drafting of the Chinese clinical practice guidelines for immunosuppressive therapy in kidney transplant recipients(2023 edition).Based upon Oxford Centre for Evidence-Based Medicine 2009 Levels of Evidence,it has addressed 20 key clinical issues,including selecting,dosage adjusting,dosing and monitoring of immunosuppressants during induction,maintenance and rejection phases in KT recipients.Incorporating both international and domestic guidelines,it also took into account the current state of KT in China.Drawing upon previous versions,the Edition 2023 has integrated the latest clinical trial evidence and provided more detailed explanations of treatment protocols,offering stronger evidence-based supports for clinical decision-making.It was intended to guide clinical practice to promote more scientific,rational and individualized dosing of immunosuppressants in KT recipients,improving long-term wellbeing and survival of both recipients and grafted kidneys.
万方数据